A framework for cost-effectiveness analysis from clinical trial data

被引:65
作者
O'Hagan, A
Stevens, JW
机构
[1] Univ Sheffield, Dept Probabil & Stat, Stat Serv Unit, Sheffield S3 7RH, S Yorkshire, England
[2] Astra Zeneca R&D Charnwood, Loughborough, Leics, England
关键词
Bayesian analysis; cost-effectiveness acceptability curve; log-normal distribution; net benefit; normal distribution; outcomes;
D O I
10.1002/hec.617
中图分类号
F [经济];
学科分类号
02 ;
摘要
We present a general Bayesian framework for cost-effectiveness analysis (CEA) from clinical trial data. This framework allows for very flexible modelling of both cost and efficacy related trial data. A common CEA technique is established for this wide class of models through linking mean efficacy and mean cost to the parameters of any given model. Examples are given in which efficacy may be measured as a continuous, binary, ordinal or time-to-event outcome, and in which costs are modelled as distributed normally, log-normally, as a mixture or non-parametrically. A case study is presented, illustrating the methodology and illuminating the role of prior information. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 26 条
  • [1] Briggs AH, 1999, HEALTH ECON, V8, P257, DOI 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO
  • [2] 2-E
  • [3] The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies
    Claxton, K
    [J]. JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) : 341 - 364
  • [4] Heitjan DF, 1999, HEALTH ECON, V8, P191, DOI 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO
  • [5] 2-R
  • [6] Jones David A., 1996, QUALITY LIFE PHARMAC
  • [7] A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US
    Lacey, L
    Mauskopf, J
    Lindrooth, R
    Pham, S
    Saag, M
    Sawyer, W
    [J]. PHARMACOECONOMICS, 1999, 15 (Suppl 1) : 23 - 37
  • [8] Laska EM, 1997, HEALTH ECON, V6, P229, DOI 10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.0.CO
  • [9] 2-M
  • [10] Cost effectiveness analysis of a dry powder inhaler (Turbuhaler(R)) versus a pressurised metered dose inhaler in patients with asthma
    Liljas, B
    Stahl, E
    Pauwels, RA
    [J]. PHARMACOECONOMICS, 1997, 12 (02) : 267 - 277